ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
University College London · St Bartholomew's Hospital · +23 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
475
total citations
- FWCI
- 22.15
- Percentile
- 100%
- References
- 85
Citations per year
Authors
16- RMRowan Miller
University College London, St Bartholomew's Hospital
- ALAlexandra Léary
Inserm, Université Paris-Saclay, Institut Gustave Roussy
- CLClare L. Scott
University of Melbourne, Peter MacCallum Cancer Centre
- VSVioleta Serra
Vall d'Hebron Institute of Oncology
- CJChristopher J. Lord
Institute of Cancer Research, Breast Cancer Now
Topics & keywords
Topics
Keywords
- Medicine
- PARP inhibitor
- Homologous recombination
- Ovarian cancer
- Biomarker
- Oncology
- Homologous chromosome
- Poly ADP ribose polymerase
No related works found for this paper.